Market Intelligence, Clinical Progress, and High-Purity Reagents for Diffuse Gastric Cancer, Metastasis Inhibition, and Related Indications Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RHOA drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RHOA WT & Mutant Proteins (Q63L, T19N, Y42C) High purity (>95%), Endotoxin <1EU/μg. Sequence Verified. Theoretical MW confirmed. |
View RHOA Products |
| Gene Delivery | RHOA Lentivirus Premade Particles Full-length ORF for stable overexpression or mutant cell line construction. HEK293 Expressed. |
View RHOA Products |
| Benchmark Ab | Anti-RHOA (Clone for IP/ICC) Recombinant positive control. Sequence Verified. |
View RHOA Products |
| Validator | RHOA siRNA Set (3 unique sequences) For knockdown verification and specificity controls. |
View RHOA Products |
| Related Target: RHOB | Critical for selectivity profiling; off-target safety assessment for Rho family inhibitors. | View RHOB Products |
| Related Target: RHOC | Metastasis driver in solid tumors; orthogonal validation for invasion assays. | View RHOC Products |
| Related Target: ARHGEF1 | Upstream GEF (Guanine nucleotide Exchange Factor); alternative druggable node for RHOA pathway activation. | View ARHGEF1 Products |
| Related Target: ROCK1 | Direct downstream effector, critical for actin cytoskeleton regulation. | View ROCK1 Products |
| Related Target: RAC1 | Synergistic GTPase pathway member for parallel pathway screening. | View RAC1 Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Nucleotide State Control (GTP vs GDP bound) | Constitutively Active (Q63L) and Dominant Negative (T19N) mutants available; purified proteins suitable for GTP-loading assays with >95% purity |
| Cross-family Selectivity (RHOA vs RHOB/C) | Human/Mouse/Cyno ortholog RHOA, RHOB, and RHOC protein panel with sequence-verified specificity for counter-screening |
| Structural & Biophysical Studies | Low endotoxin (<1 EU/μg) and high-concentration (≥5 mg/mL) formulation suitable for crystallography and SPR |
| Lack of Cellular Controls | Validated siRNA included for knockdown specificity confirmation; Lentivirus for rescue experiments |
| Mutant-Specific Drug Development (Y42C) | Cancer-associated Y42C and G17E mutant proteins available; Sequence-verified for diffuse gastric cancer targeting |
| Evaluating Drug Resistance and Cancer-Specific Mutations | Gastric cancer specific mutants (e.g., Y42C) available with strict Sequence Verification and High Purity (>95%) |
| Targeting Intracellular Conformations | E. coli or HEK293 expressed soluble proteins optimized for structural integrity and nucleotide binding assays |
| Lack of Reliable Assay Controls | Recombinant positive control antibodies included for standardized Western Blot and ELISA workflows |
| Target Validation & False Positives | Sequence-verified siRNA included for precise cellular specificity checks and knockdown validation |
Live RHOA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RHOA-targeted therapeutics is intensifying, with major players shifting focus from direct enzyme inhibition to upstream Guanine nucleotide Exchange Factor (GEF) blockade, allosteric inhibition, and PROTAC-mediated degradation. As a critical molecular switch in the GTPase family, RHOA plays a central role in tumor metastasis, angiogenesis, and cardiovascular pathology. Recurrent Y42C and G17E mutations in diffuse gastric cancer (DGC) reveal novel druggable pockets, driving next-wave R&D toward mutant-selective inhibitors and degraders, as well as combination therapies with immune checkpoint inhibitors. The field is also exploring alternative strategies such as ROCK inhibitor-based pathway blockade and RNAi therapeutics for fibrosis and pulmonary hypertension.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| GEF Inhibitors (Indirect) | Asahi Kasei, AstraZeneca | Diffuse Gastric Cancer | GTP-loading Assay (Need WT vs Mutant RHOA proteins with controlled nucleotide states) |
| PROTACs / Molecular Glues | Arvinas, C4 Therapeutics, and other early-stage innovators | Solid Tumors (Metastatic), Metastatic Cancers | Mutant Selectivity Panel and Ternary Complex Validation (Need Y42C, G17E mutants vs WT; strictly sequence-verified RHOA) |
| ROCK Inhibitors (Downstream) | Kowa Company, D. Western Therapeutics | Glaucoma, Cancer | Pathway Activation Assay (Need RHOA mutants to verify upstream pathway blockade) |
| Gene Therapy (siRNA/mRNA) | Silence Therapeutics | Fibrosis | Knockdown Validation (Need high-efficiency siRNA and lentiviral delivery systems) |
| Small Molecule Inhibitors (Direct/Allosteric) | Various Oncology Biotechs | Gastric Cancer, Solid Tumors | Binding Assays (Need High-purity Wild-Type and Y42C Mutant Proteins) |
| RNAi / Gene Therapy | Cardiovascular Developers | Pulmonary Hypertension | In Vitro Knockdown Assays (Need specific siRNA and benchmark detection Abs) |